Targeted biological therapies reach the heart: the case of serelaxin for heart failure.

VA Kumar, SS Wilson, SI Ayaz… - Drugs of Today (Barcelona …, 2015 - europepmc.org
Acute heart failure (AHF) is one of the most important causes of mortality, morbidity and
rising healthcare costs. Despite this, there has been minimal advancement in the …
被引用次数：5 相关文章

TARGETED BIOLOGICAL THERAPIES REACH THE HEART: THE CASE OF SERELAXIN FOR HEART FAILURE

VA Kumar, SS Wilson, SI Ayaz, PD Levy - Drugs of Today, 2015 - access.portico.org
Acute heart failure (AHF) is one of the most important causes of mortality, morbidity and
rising healthcare costs. Despite this, there has been minimal advancement in the …

Targeted biological therapies reach the heart: the case of serelaxin for heart failure

VA Kumar, SS Wilson, SI Ayaz… - Drugs of today …, 2015 - pubmed.ncbi.nlm.nih.gov
Acute heart failure (AHF) is one of the most important causes of mortality, morbidity and
rising healthcare costs. Despite this, there has been minimal advancement in the …

Targeted biological therapies reach the heart: the case of serelaxin for heart failure.

AV Kumar, AS Wilson, SI Ayaz… - … de actualidad= Drugs of …, 2015 - dialnet.unirioja.es
Acute heart failure (AHF) is one of the most important causes of mortality, morbidity and
rising healthcare costs. Despite this, there has been minimal advancement in the …

TARGETED BIOLOGICAL THERAPIES REACH THE HEART: THE CASE OF SERELAXIN FOR HEART FAILURE

VA Kumar, SS Wilson, SI Ayaz, PD Levy - Drugs of Today, 2015 - access.portico.org
Acute heart failure (AHF) is one of the most important causes of mortality, morbidity and
rising healthcare costs. Despite this, there has been minimal advancement in the …